No Image

EMEcs Project Online Workshop

November 28, 2022 AutoBot 0

OSH events Back to events EMEcs Project Online Workshop Event Details Location Online City Brussels Country Belgium Organisation AEIP – European Association of Paritarian Funds […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

November 28, 2022 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

New tentative approval for Amneal Pharms drug saxagliptin

November 28, 2022 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]

No Image

Conference & CLE Calendar

November 28, 2022 AutoBot 0

November 28, 2022 – "UPC Judges Released — A Conversation on the Unified Patent Court" (OxFirst Limited) – 15:30 to 16:30 (GMT) November 29, 2022 […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

November 27, 2022 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

New tentative approval for Amneal Pharms drug saxagliptin

November 27, 2022 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]

No Image

IPO Webinar on Ethics Issues in IP

November 27, 2022 AutoBot 0

The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Ethics Issues in IP: Transactions, Prosecution, and Litigation" on November 29, 2022 from […]

No Image

New tentative approval for Amneal Pharms drug saxagliptin

November 26, 2022 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

November 26, 2022 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

Guidance Webinar Series

November 25, 2022 AutoBot 0

FDA’s Guidance Webinar series aims to foster collaboration and transparency in the development of guidance documents through direct outreach to affected stakeholders.

No Image

New tentative approval for Teva Pharms drug eltrombopag

November 25, 2022 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

New tentative approval for Amneal Pharms drug saxagliptin

November 25, 2022 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]

No Image

New tentative approval for Amneal Pharms drug saxagliptin

November 24, 2022 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

November 24, 2022 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

WHO lands on new name for monkeypox

November 23, 2022 AutoBot 0

The World Health Organization will rename monkeypox “MPOX” in an effort to destigmatize the virus amid growing pressure from senior Biden administration officials, Politico reported […]

No Image

Hospital CEO exits slow

November 23, 2022 AutoBot 0

Eighty-five hospital CEOs exited their roles in the first 10 months of this year, down 10.5 percent from the 95 chiefs who stepped down from […]